Healthcare Services company Suven Life Sciences announced Q2FY26 results Revenue: Rs 46.97 million against Rs 66.09 million during Q2FY25. PAT: Rs -773.10 million against Rs -496.44 million during Q2FY25. EPS: Rs -3.48 for Q2FY26. Clinical development pipeline: SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of calander 2026. SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by end of fiscal 2026. SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA and expected completion by end of calander 2026. SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during 2026. SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics of the molecule. Anticipated completion by fiscal 2026. Result PDF
Healthcare Services company Suven Life Sciences announced Q1FY26 results Revenue: Rs 24.67 million compared to Rs 50.14 million during Q1FY25. PAT: Rs -515.17 million compared to Rs -280.40 million during Q1FY25. EPS: Rs -2.36 for Q1FY26. Result PDF
Healthcare Services company Suven Life Sciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue: Rs 26.90 million compared to Rs 66.68 million during Q4FY24. PAT: Rs -439.45 million compared to Rs -265.41 million during Q4FY24. EPS: Rs -2.02 compared to Rs -1.22 million during Q4FY24. FY25 Financial Highlights: Revenue: Rs 175.53 million compared to Rs 328.23 million during FY24. PAT: Rs -1,607.45 million compared to Rs -1,050.76 million during FY24. EPS: Rs -7.37 compared to Rs -4.82 million during FY24. Result PDF
Healthcare Services company Suven Life Sciences announced Q3FY25 results Revenue: Rs 32.40 million compared to Rs 85.16 million during Q3FY24. PAT: Rs -391.17 million compared to Rs -417.65 million during Q3FY24. EPS: Rs -1.79 for Q3FY25. Clinical development pipeline: SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of FY26. SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q1FY26. SUVN-911 (Ropanicant) – Phase 2A open label study for Major Depressive Disorder in USA successfully completed. Preparing to start Phase 2B clinical study in Q1FY26. SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition in MDD during FY26. SUVN-I6107 – Phase 1 study initiated during FY25 is continuing for establishing safety and pharmacokinetics of the molecule. Result PDF
Pharmaceuticals company Suven Life Sciences announced Q2FY25 results Revenue: Rs 66.09 million, compared to Rs 82.01 million during Q2FY24. PAT/Loss: Rs -496.44 million, compared to Rs 126.80 million during Q2FY24. EPS: Rs -2.27, compared to Rs -0.58 during Q2FY24. Result PDF